Key opinion leader (KOL) input is associated with a higher success rate in drug development. However, many oncology programs fail to effectively use this critical resource, resulting in poor decision ...

Ellipses Pharma has implemented a disruptive approach to cancer drug development that greatly accelerates the delivery of novel solutions for patients. With seven lead products and a growing pipeline ...

Guaranteed success in drug development does not exist, such are the inherent risks, potential pitfalls and costs involved. But UK-based Ellipses Pharma has developed a model that - if its founder’s ...

A drug development company focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting, to de-risk initial asset selection ...

LONDON--(BUSINESS WIRE)--Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development ...